

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
28 November 2024 (28.11.2024)



(10) International Publication Number
WO 2024/243323 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) *A61P 21/00* (2006.01)
A61K 39/00 (2006.01) *A61P 25/00* (2006.01)
A61P 19/00 (2006.01) *A61P 19/02* (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(21) International Application Number:

PCT/US2024/030593

(22) International Filing Date:

22 May 2024 (22.05.2024)

(25) Filing Language:

English

(26) Publication Language:

English

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(30) Priority Data:

23174655.3 22 May 2023 (22.05.2023) EP
23174657.9 22 May 2023 (22.05.2023) EP

(71) Applicant: **GENZYME CORPORATION** [US/US]; 450 Water Street, Cambridge, Massachusetts 02141 (US).

(72) Inventors: **FARENC, Christine**; c/o Sanofi, Patent Department, 450 Water Street, Cambridge, Massachusetts 02141 (US). **TRUFFINET, Philippe**; c/o Sanofi, Patent Department, 450 Water Street, Cambridge, Massachusetts 02141 (US). **SCHUMACHER, Fabienne**; c/o Sanofi, Patent Department, 450 Water Street, Cambridge, Massachusetts 02141 (US).

(74) Agent: **LI, Z. Ying** et al.; Steptoe & Johnson LLP, 1330 Connecticut Avenue, N.W., Washington, District of Columbia 20036 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: TREATMENT OF MULTIPLE SCLEROSIS WITH ANTI-CD40L ANTIBODIES

(57) Abstract: The present invention relates to treatment of relapsing forms of multiple sclerosis using an anti-human CD40L monoclonal antibody.

WO 2024/243323 A1